Molecule Type:
Small Molecules: The segment of small molecules is expected to dominate the sterile injectable contract manufacturing market due to the high demand for generic small molecule drugs and the ease of manufacturing them.
Biologics: The biologics segment is anticipated to grow at a rapid pace, driven by the increasing adoption of biologics for the treatment of various diseases and the advancements in bioprocessing technologies.
Route of Administration:
Intravenous: The intravenous route of administration is the most common for sterile injectables, accounting for a significant share of the market due to the quick onset of action and high bioavailability.
Intramuscular: The intramuscular route of administration is also widely used, especially for vaccines and certain medications that need to be slowly released into the bloodstream.
Therapeutic Application:
Oncology: The oncology segment is expected to be the largest in terms of therapeutic application, driven by the increasing prevalence of cancer and the growing demand for oncology drugs.
Infectious Diseases: The infectious diseases segment is anticipated to witness significant growth, fueled by the rising cases of infectious diseases and the need for effective treatments.
End-use:
Pharmaceutical Companies: Pharmaceutical companies are the major end-users of sterile injectable contract manufacturing services, as they outsource the manufacturing of sterile injectables to focus on research and development.
Biotechnology Companies: Biotechnology companies are also significant end-users, especially for the production of biologics and other specialty drugs that require specialized manufacturing processes.